Company intelligence / Profile preview

Tara Immuno-Oncology

Ownership: Private
Development stage: Phase 2

Overview

Tara Immuno-Oncology licensed two preclinical immuno-oncology assets (p53MVA, a vaccinia viral vector delivering wild-type p53 antigen, and shIDO-ST, a Salmonella-based therapy targeting indoleamine 2,3-dioxygenase) from City of Hope for development in oncology indications. No clinical results have been published; the company’s current operational status is unclear and it has had no major updates since 2015.

Therapeutic areas: Oncology
Modalities: Viral vector-based therapyBacterial therapy
Industry: Biotech

Drug pipeline

2 assets

TARA-002

Phase 2

Indications: Non-muscle invasive bladder cancer, Lymphatic malformations

1 more asset in the full pipeline.

Request access →

Partnerships

City of Hope

Beyond the preview

Go deeper on Tara Immuno-Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tara Immuno-Oncology.

Explore the full profile